Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
Page
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
Read More
Blog
Cancer Research and Clinical Development Since Last ASCO
Read Story
Blog
The Need for More Elderly Patients in Cancer Clinical Trials
Read Story
View all related content and resources for Oncology
Explore Insights